louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04169464: The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral Therapy
Official title: The Renal Safety and Rates of Acute Kidney Injury (AKI) in Patients With Chronic HCV Undergoing Sofosbuvir Containing Direct Acting Antiviral Therapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Egyptian Patients, HCV Treatment, Kidney Function
Keywords: HCV
DAAs
Egyptian patients
creatinine
insulin resistence
GFR
Lead sponsor: MTI University
Sponsor class: OTHER
First posted: 2019-11-19
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate the occurrence of AKI during antiviral therapy, when compared with baseline values in Egyptian patients.

In addition, the study aims to evaluate the change in insulin resistance value after treating patients from HCV.

Detailed description: There are limited published data, currently, suggesting the risk of AKI during oral direct acting antiviral treatment. Most case reports and retrospective studies reported the presence of an intrinsic cause of renal injury, with most of the available biopsies showing acute tubular necrosis (ATN) and acute interstitial nephritis (AIN). Most of these patients had returned to baseline renal function on cessation of sofosbuvir combination therapy.

Recently it was found that a notable percentage of patients experienced a transient increase in creatinine during therapy, which could occasionally lead to a more than 50% decrease in patients' eGFR. Previous studies had also shown that the co-use of nonsteroidal anti-inflammatory drugs (NSAIDs) and recurrent ascites were at increased risk for AKI during sofosbuvir-based antiviral therapy (Brawn et al., 2018).

The primary endpoint of this study is to investigate the occurrence of AKI in Egyptian patients during antiviral therapy and to highlight its reasons and time of incidence in addition to the mechanism of this injury.

Eligibility criteria: Inclusion Criteria:

* Age≥ 18 years Chronic infection with HCV GT 4 No prior HCV treatment experience

Exclusion Criteria:

* Co-infection with HBV or HIV, clinical evidence of ischemic heart disease, the presence of diabetic ketoacidosis, Patients admitted to the intensive care unit (ICU), or expected to undergo surgery during the study period, and Child Pough score C.

Primary outcomes:
measure: occurance of AKI during therapy
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Thabet Thabet hospital
Study officials:
affiliation: Lecturer of pharmacology and toxicology
name: Dalia Zaafar, Phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02770664: Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: ST-segment Elevation Myocardial Infarction
Lead sponsor: LG Life Sciences
Sponsor class: INDUSTRY
First posted: 2016-05-12
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before Percutaneous Coronary Intervention (PCI) in Patients with ST-segment Elevation Myocardial Infarction (STEMI).


Eligibility criteria: Inclusion Criteria:

* Age between 20 and 75
* Within 12 hours after the onset of chest pain
* ST-segment elevation of more than 0.1 mV in two contiguous leads or new left bundle-branch block (LBBB) patients
* Signed for written informed consent

Exclusion Criteria:

* Left Main disease
* Multi-vessel disease

Primary outcomes:
measure: AUC of Troponin I for 72 hours post PCI
timeFrame: pre PCI, PCI 0h, 6h, 12h, 18h, 24h, 48h, 72h
Secondary outcomes:
measure: AUC of CK-MB for 72 hours post PCI
timeFrame: pre PCI, PCI 0h, 6h, 12h, 18h, 24h, 48h, 72h
measure: AUC of CK for 72 hours post PCI
timeFrame: pre PCI, PCI 0h, 6h, 12h, 18h, 24h, 48h, 72h
measure: Infarct size assessed by Cardiac MRI
timeFrame: Day 4, 30
measure: Myocardial function assessed by Cardiac MRI
timeFrame: Day 4, 30
measure: Myocardial function assessed by Echocardiogram
timeFrame: Day 4, 30
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT04205864: Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer.
Official title: Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lymphocele
Lymphocele After Surgical Procedure
Endometrium Cancer
Lead sponsor: Kocaeli University
Sponsor class: OTHER
First posted: 2019-12-20
Enrollment: 72
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Application of Thrombin gel matrix after Pelvic lymphadenectomy. And compare this application with Conventional Pelvic Lymphadenectomy.
Primary purpose: PREVENTION

Brief summary: To compare the incidence of lymphocele in Endometrial cancer patients with thrombin gel matrix used and not used during pelvic lymph node dissection.

Detailed description: Pelvic lymph node dissection is the most accurate staging tool to determine lymph node involvement in endometrial cancer. Lymphoceles developed after surgery can cause serious morbidity, additional costs and delays in chemotherapy or radiotherapy. In this study, conventional pelvic lymphadenectomy will be compared with thrombin gel matrix application after pelvic lymphadenectomy. Our goal is to prospectively assess the lymphostatic effect of thrombin gel matrix in endometrial cancer patients undergoing pelvic lymph node dissection.

Eligibility criteria: Inclusion Criteria:

* Endometrial cancer patients who need laparotomic bilateral PLND
* Patients suitable for surgery

Exclusion Criteria:

* Previous pelvic surgery
* Previous Chemotherapy or Radiotherapy
* Patients who undergo only lymph node sampling
* Patients who have not signed Informed Consent

Primary outcomes:
measure: Frequency of pelvic lymphocele
timeFrame: post-operative 2th month
Secondary outcomes:
measure: Volume of radiographic lymphoceles
timeFrame: post-operative 2th month
measure: duration of postoperative drainage catheter
timeFrame: up to post-operative 1 week
measure: Postoperative drain amount (ml: milliliters)
timeFrame: with 1 weeks after surgery
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Kocaeli University
Study officials:
affiliation: Kocaeli University
name: Şener Gezer, M.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim YH, Shin HJ, Ju W, Kim SC. Prevention of lymphocele by using gelatin-thrombin matrix as a tissue sealant after pelvic lymphadenectomy in patients with gynecologic cancers: a prospective randomized controlled study. J Gynecol Oncol. 2017 May;28(3):e37. doi: 10.3802/jgo.2017.28.e37. Epub 2017 Feb 28.
Clinical trial NCT01752764: Assessment of the Relative Increase in Bioavailability of (Non-) Nutrients From a Mixed Salad by Adding Fat Containing Dressing
Official title: Assessment of the Relative Increase in Bioavailability of (Non-) Nutrients From a Mixed Salad by Adding Fat Containing Dressing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Subjects
Lead sponsor: Unilever R&D
Sponsor class: INDUSTRY
First posted: 2012-12-19
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The hypothesis will be tested that fat can also increase absorption of (non)-nutrients from a salad. Therefore we designed the current study to show an increase in relative absorption (bioavailability) of (non-) nutrients from a mixed salad by adding fat containing dressing.


Eligibility criteria: Main inclusion Criteria:

* Body mass index (BMI) ≥ 18.5 and ≤ 30.0 kg/m2.
* Apparently healthy: no medical conditions, no use of prescribed or over the counter drugs, which might affect study measurements (as judged by study physician)
* Haemoglobin within normal reference range as judged by the study physician.
* Total cholesterol, LDL cholesterol, HDL cholesterol and fasting triglycerides within the normal reference range, as judged by the study physician.

Main exclusion Criteria:

* Reported use of any medically- or self-prescribed diet at the moment of screening, or the intention to use any kind of diet in the period between screening and the end of the study.
* Reported weight loss or gain ≥ 10 % of bodyweight during a period of six months before screening.
* A known food allergy or intolerance.
* A dislike to the foods supplied during the study.
* Use of vitamins or supplements enriched with carotenoid and/or vitamin A and/of vitamin K.
* Known hypothyroidism or hyperthyroidism.

Primary outcomes:
measure: Area under the curve (AUC in nmol/l*h) of (non) nutrients
timeFrame: July 2013
Secondary outcomes:
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Instituto do Coração - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo / Incor HC FM USP
state: Av. Dr. Enéas de Carvalho Aguiar, 44
Study officials:
affiliation: Head Professor of Clinical Biochemistry, Faculty of Pharmaceutical Sciences Director, Lipid Metabolism Laboratory
name: Dr. Raul C. Maranhão, M.D, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02547064: Effect of Modified Stylet Angulation on the Intubation With GlideScope®
Official title: Stylet Angulation of Seventy Degrees Reduced Time to Intubation With the GlideScope®: A Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cholecystitis
Stomach Cancer
Keywords: intubation
stylet
videolaryngoscope
Lead sponsor: Keimyung University Dongsan Medical Center
Sponsor class: OTHER
First posted: 2015-09-11
Enrollment: 162
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The GlideScope® videolaryngoscope usually visualize glottis better than the conventional laryngoscope. Under the visualization of glottis by GlideScope®, the insertion of endotracheal tube, however, is challenging.

The goal of this study was to determine which of two stylet (70° vs 90°) was better, as determined by time to intubation.


Eligibility criteria: Inclusion Criteria:

* Patients requiring endotracheal intubation for general anesthesia

Exclusion Criteria:

* Difficult airway
* Rapid sequence induction
* Recent sore throat
* Fragile teeth
* Contraindication for videolaryngoscope
* Head and neck surgery

Primary outcomes:
measure: Time to Intubation
timeFrame: Intraoperative intubation
Secondary outcomes:
measure: Success Rate of Intubation
timeFrame: Intraoperative intubation
measure: Difficulty of Intubation Measured Using Visual Analogue Scale
timeFrame: Intraoperative intubation
measure: Number of Participants for Whom External Laryngeal Manipulation Was Necessary
timeFrame: Intraoperative intubation
measure: Cormack-Lehan Grade
timeFrame: Intraoperative intubation
measure: Mallampati Grade
timeFrame: Intraoperative anesthetic induction
measure: Thyromental Distance
timeFrame: Intraoperative anesthetic induction
measure: Postoperative Sore Throat Measured Using Visual Analogue Scale
timeFrame: at 1, 24 hr postoperatively
measure: Mean Blood Pressure
timeFrame: Intraoperative intubation
measure: Heart Rate
timeFrame: Intraoperative intubation
measure: Airway Injury
timeFrame: Intraoperative intubation
Other outcomes:
Locations:
Study officials:
References:
citation: Lee YC, Lee J, Son JD, Lee JY, Kim HC. Stylet angulation of 70 degrees reduces the time to intubation with the GlideScope(R): A prospective randomised trial. J Int Med Res. 2018 Apr;46(4):1428-1438. doi: 10.1177/0300060517741065. Epub 2018 Jan 14.
Clinical trial NCT01406964: Chlamidia Antibodies Test for Tubal Factor Screening
Official title: Chlamidia Antibodies Test for Tubal Factor Screening
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sterility
Keywords: Chlamidia Antibody test, Hysterosalpyngography, Tubal disease
Lead sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA
Sponsor class: OTHER
First posted: 2011-08-01
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to evaluate the usefulness of a Chlamydia Antibody Test for screening of tubal factor in patients who undergo artificial insemination.


Eligibility criteria: Inclusion Criteria:

* Age \< 38 years
* FSH \< 12.
* Treatment intrauterine insemination

Exclusion Criteria:

* Insulin dependent diabetes
* Thyroid disease
* Severe male factor
* Policystic ovarian syndrome
* Previous abdominal or uterine surgery
* Prevous abdominal or genital infections
* Uterine myomas
* Hidrosalpinx
* Uterine congenital abnormalities

Primary outcomes:
measure: Pregnancy outcome using the two different treatments.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: IVI Valencia
Study officials:
References:
Clinical trial NCT00160264: Study to Investigate if Adding Lactulose to Vitamin D and Calcium Has an Effect on the Preservation of Bone in Postmenopausal Women
Official title: A Randomized, Double-Blind, Multicenter, Parallel Pilot Clinical Trial to Study the Efficay of a Treatment of Lactulose + Vitamin D + Calcium 0.5 g Concurrently Controlled With a Standard Treatment (Vit D + Calcium) in Bone Mass Preservation Among Postmenopausal Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Osteopenia
Keywords: lactulose; randomised clinical trial; osteopenia; postmenopause
Lead sponsor: Solvay Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2005-09-12
Enrollment: 40
Sex: FEMALE
Minimum age (years): 55
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: This is a randomized, double-blind, multicentre, parallel pilot clinical trial to study the efficacy of a treatment of lactulose 15 ml + vitamin D 400 U + calcium 0.5 g compared to lactulose placebo 15 ml + vitamin D 400 U + calcium 1 g in bone mass preservation among postmenopausal women.


Eligibility criteria: Inclusion Criteria:

Women aged between 55 and 65 years old; postmenopausal who have amenorrhea for 5 or more years; women with the diagnosis of osteopenia defined DMO -1,5 to -2,5

Exclusion Criteria:

Any disease causing osteopenia (hyperthyroidism, hyperparathyroidism, hypercortisolism, osteogenesis imperfecta, rheumatoid arthritis, homocystinuria, etc.)

Primary outcomes:
measure: bone mass preservation by bone densitometry values in 1 year period
Secondary outcomes:
measure: evolution of bone remodelling parameters
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Site 1
city: Barcelona
country: Spain
facility: Site 2
city: Barcelona
country: Spain
facility: Site 3
Study officials:
affiliation: Solvay Pharmaceuticals
name: Global Clinical Director Solvay
role: STUDY_DIRECTOR
References:
Clinical trial NCT02242864: Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure
Official title: Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-09-17
Enrollment: 1527
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Outpatients with hypertension and diabetes mellitus

Brief summary: The primary objective was to evaluate the effect of the treatment with Micardis® or MicardisPlus® on blood pressure. Secondary objectives were the effect of Micardis® / MicardisPlus® on metabolic parameters (triglycerides, cholesterol, LDL blood glucose, insulin Homeostasis Model Assessment (HOMA)-index and HbA1c) in patients with essential hypertension and diabetes mellitus


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Hypertension
* Diabetes mellitus

Exclusion Criteria:

* Age \< 18 years

Primary outcomes:
measure: Change from Baseline in systolic blood pressure (SBP)
timeFrame: Baseline, after 6 months
measure: Change from Baseline in diastolic blood pressure (DBP)
timeFrame: Baseline, after 6 months
Secondary outcomes:
measure: Assessment of efficacy by investigator on a 6-point scale
timeFrame: after 6 months
measure: Assessment of metabolic effect on a 3-point scale
timeFrame: after 6 months
measure: Change from Baseline in laboratory parameters
timeFrame: Baseline, after 6 months
measure: Assessment of tolerability by investigator on a 5-point scale
timeFrame: after 6 months
measure: Number of patients with adverse events
timeFrame: up to 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01756664: The Use of Sunscreen Starting on the First Day After Ablative Fractional Skin Resurfacing
Official title: The Use of Sunscreen Starting on the First Day After Ablative Fractional Skin Resurfacing - A Pilot Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: PIH
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2012-12-27
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: - The use of sunscreen on the first day after fractional ablative skin resurfacing may reduce the risk of post-inflammatory hyperpigmentation

Detailed description: * The use of sunscreen on the first day after fractional ablative skin resurfacing may reduce the risk of post-inflammatory hyperpigmentation (PIH)
* Therefore, we conducted the study to evaluate the efficacy of the use of sunscreen on the first day after fractional ablative skin resurfacing in reducing the risk of PIH.

Eligibility criteria: Inclusion Criteria:

* Patients who want to receive fractional ablative laser resurfacing for acne scars

Exclusion Criteria:

* Pregnancy
* Lactation
* Age \< 18

Primary outcomes:
measure: Melanin Index
timeFrame: 3 Month
Secondary outcomes:
measure: Erythema Index
timeFrame: 3 Months
Other outcomes:
measure: Transepidermal Water Loss
timeFrame: 1 Week
Locations:
city: Bangkok
country: Thailand
facility: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
Study officials:
References:
Clinical trial NCT01663064: Zenith® p-Branch™: Single-Center Study
Official title: Zenith® p-Branch™: Single-Center Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aortic Aneurysm
Abdominal Aortic Aneurysm
Keywords: Abdominal aortic aneurysm
Endovascular
Fenestration
Juxtarenal
Off-the-shelf
Pararenal
Lead sponsor: Cook Group Incorporated
Sponsor class: INDUSTRY
First posted: 2012-08-13
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The Zenith® p-Branch™: Single-Center Study is a clinical trial approved by Swedish Regulatory Authority to study the safety and effectiveness of the Zenith® p-Branch™ in the treatment of abdominal aortic aneurysms.


Eligibility criteria: Inclusion Criteria:

* Pararenal or juxtarenal AAA \>5.0 cm in diameter
* Pararenal or juxtarenal AAA with history of growth \>0.5 cm/year

Exclusion Criteria:

* Age \< 18 years
* Life expectancy \< 2 years
* Pregnant or breast feeding
* Inability or refusal to give informed consent by the patient or a legally authorized representative
* Unwilling or unable to comply with the follow-up schedule
* Additional medical restrictions as specified in the Clinical Investigation Plan
* Additional anatomical restrictions as specified in the Clinical Investigation Plan

Primary outcomes:
measure: Technical Success
timeFrame: Up to 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Malmo
country: Sweden
facility: Skane University Hospital
Study officials:
affiliation: Skane University Hospital
name: Timothy A. Resch, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01166464: Examining a Text Message Intervention for Smoking Cessation
Official title: Examining a Text Message Intervention for Smoking Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tobacco Use Disorder
Nicotine Dependence
Keywords: tobacco
smoking
text message
therapy
Lead sponsor: The Miriam Hospital
Sponsor class: OTHER
Collaborators: name: Live Inspired, LLC
First posted: 2010-07-21
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary goal of this study is to use qualitative interviews and focus groups to aid us in adapting a face-to-face smoking cessation intervention for delivery through text messaging. After design is completed, the intervention will be pilot tested with a sample of young adults (ages 18-35) who smoke. Final assessments will be conducted at 7 weeks (end of treatment) and both 3 and 6 month follow up.


Eligibility criteria: Inclusion Criteria:

* Age 18 to 35
* Current daily smoker
* Has a cell phone with text messaging capability
* Uses text messaging at least once monthly
* Interested in quitting smoking
* Willing to set a quit date within the next 30 days
* Has access to a physician

Exclusion Criteria:

* Does not read and speak English with adequate comprehension
* Is currently participating in a smoking cessation program
* Concurrent drug/alcohol abuse
* Mental health issues that would interfere with study compliance

Primary outcomes:
measure: Smoking abstinence
timeFrame: Six months post-treatment
Secondary outcomes:
measure: Usability and Acceptability of the intervention
timeFrame: 7 weeks (end of treatment)
Other outcomes:
Locations:
city: Providence
country: United States
facility: The Miriam Hospital
state: Rhode Island
Study officials:
affiliation: The Miriam Hospital, Brown Medical School
name: Beth C Bock, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bock B, Heron K, Jennings E, Morrow K, Cobb V, Magee J, Fava J, Deutsch C, Foster R. A Text Message Delivered Smoking Cessation Intervention: The Initial Trial of TXT-2-Quit: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2013 Jul 30;1(2):e17. doi: 10.2196/mhealth.2522.